← Back to Search

Combination Chemotherapy

Hydroxyurea + Chemotherapy for Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Ottawa Regional Cancer Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histopathologically proven non-small cell lung cancer that is incurable by surgery or radiotherapy

Cardiovascular: No uncontrolled hypertension or other cardiac disease, No myocardial infarction within 6 months

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well hydroxyurea works with combination chemotherapy in treating patients with non-small cell lung cancer.

Who is the study for?

This trial is for adults with non-small cell lung cancer that can't be cured by surgery or radiation. They must have shown resistance to previous chemotherapy, have a life expectancy over 12 weeks, and their major organs need to function well. People with uncontrolled health issues like high blood pressure, recent heart attacks, severe infections, or mental status changes cannot join.Check my eligibility

What is being tested?

The study is testing the effectiveness of hydroxyurea combined with other chemotherapy drugs in patients who have non-small cell lung cancer and haven't responded well to prior treatments. It's a Phase I trial focused on understanding how these drugs work together to stop cancer cells from growing.See study design

What are the potential side effects?

Chemotherapy can cause side effects such as fatigue, nausea, vomiting, hair loss, increased risk of infection due to low blood counts (like white cells), mouth sores and diarrhea. Hydroxyurea may also cause skin rash and drowsiness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer cannot be cured with surgery or radiation.

Select...

My blood pressure is controlled and I haven't had a heart attack in the last 6 months.

Select...

My kidney function is good, with creatinine below 1.6 mg/dL.

Select...

I am 18 years old or older.

Select...

I can take care of myself and am up and about more than 50% of my waking hours.

Select...

My liver function tests are within normal limits.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ottawa Regional Cancer CentreLead Sponsor

6 Previous Clinical Trials

452 Total Patients Enrolled

David J. Stewart, MD, FRCPCStudy ChairOttawa Regional Cancer Centre

Media Library

Combination Chemotherapy (Combination Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00002887 — Phase 1

Lung Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00002887 — Phase 1

Combination Chemotherapy (Combination Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002887 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks are associated with this treatment?

"Our assessment of this treatment's safety was a cautious 1 as it is only in Phase 1. This suggests there are limited findings supporting its efficacy and security."

Answered by AI

Are there currently any openings in this clinical evaluation?

"The clinical trial was made available on July 1st 1995 and underwent its last revision in September 2013. This indicates that the study is not presently looking for participants, however there are 2,041 other medical trials taking part at this time which may qualify potential recruits."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer

1995. "Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002887.

All > Lung > Sclc